Mar 14 |
NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy
|
Mar 13 |
NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia
|
Mar 12 |
Echo Lake Capital Issues Top Ten List of Reasons Why Shai Gozani, CEO of Neurometrix Inc., Should Be Fired
|
Mar 8 |
RS FUND LP Calls for Immediate Action and Capital Return in Neurometrix, Inc.
|
Mar 4 |
Echo Lake Capital Calls for the Liquidation of Neurometrix, Inc.
|
Feb 24 |
NeuroMetrix Full Year 2023 Earnings: US$6.08 loss per share (vs US$4.96 loss in FY 2022)
|
Feb 23 |
NeuroMetrix, Inc. (NASDAQ:NURO) Q4 2023 Earnings Call Transcript
|
Feb 23 |
Q4 2023 NeuroMetrix Inc Earnings Call
|
Feb 22 |
NeuroMetrix, Inc. (NURO) Q4 2023 Earnings Call Transcript
|
Feb 22 |
NeuroMetrix GAAP EPS of -$1.43, revenue of $1.32B
|